Androgen supplementation in assisted reproduction: where are we in 2019?
| Autor: | Pedro Montoya-Botero, Jorge Rodriguez-Purata, Nikolaos P. Polyzos |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Future studies
POOR RESPONDERS medicine.medical_treatment DEHYDROEPIANDROSTERONE Bioinformatics DOUBLE-BLIND Mice 0302 clinical medicine MARKERS Ovarian Follicle Pregnancy Testosterone media_common Ovarian Function Tests Mice Knockout Clinical Trials as Topic 030219 obstetrics & reproductive medicine Pregnancy Outcome WOMEN Obstetrics and Gynecology FOLLICULAR DEVELOPMENT POLYCYSTIC-OVARY-SYNDROME TRANSDERMAL TESTOSTERONE 030220 oncology & carcinogenesis in-vitro fertilization Androgens Female Animal studies Reproduction Adult Reproductive Techniques Assisted medicine.drug_class media_common.quotation_subject MEDLINE androgen poor ovarian responder CONTROLLED-TRIAL Administration Cutaneous 03 medical and health sciences Ovulation Induction medicine Animals Humans Infertility therapy business.industry Ovary Dehydroepiandrosterone Androgen medicine.disease Infertility testosterone Ovulation induction business |
| Zdroj: | Montoya-Botero, P, Rodriguez-Purata, J & Polyzos, N P 2019, ' Androgen supplementation in assisted reproduction : where are we in 2019? ', Current Opinion in Obstetrics & Gynecology, vol. 31, no. 3, pp. 188-194 . https://doi.org/10.1097/GCO.0000000000000532 |
| ISSN: | 1473-656X |
| DOI: | 10.1097/GCO.0000000000000532 |
| Popis: | Purpose of reviewThe purpose of this review is to provide an overview of androgen supplementation in ART with the most updated evidence, from animal studies to its clinical applications in poor ovarian responders (POR) and the future studies to be published.Recent findingsAnimal studies, has shown that testosterone supplementation, can be an option to increase the recruitable follicular pool in POR. However, the potential mechanism of action, dose, and duration of treatment is still under investigation. Early studies in humans reported promising results in favor of androgens [dehydroepiandrosterone (DHEA) or testosterone] in POR. Nevertheless, recent evidence does not appear to follow the initial results, whereas the type, dose, and duration of testosterone administration appear to be crucial for treatment effect.SummaryTestosterone seems to play an essential role in regulating ovarian function. However, it is worrisome that androgens are used off-label, despite that the available evidence is weak. Although testosterone supplementation may be beneficial in POR, published studies have used inconsistent doses and duration of administration. An ongoing trial (T-TRANSPORT trial) for the first time aims to provide conclusive evidence on whether transdermal testosterone administration can improve the reproductive outcomes in patients undergoing IVF/ICSI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|